Promising human brain tumors therapy with interference RNA intervention (iRNAi)

Related Experiment Video

Updated: Jun 16, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Katarzyna Rolle1, Stanislaw Nowak, Eliza Wyszko

  • 1Institute of Bioorganic Chemistry of the Polish Academy of Sciences, Poznan, Poland.

Cancer Biology & Therapy
|February 2, 2010
PubMed

Insights

This study introduces a novel RNA interference therapy targeting tenascin-C (TN-C) in glioblastoma multiforme patients. The treatment demonstrated improved survival and delayed tumor recurrence, offering a promising new approach for brain tumor treatment.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • RNA therapeutics

Background:

  • Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.
  • Tenascin-C (TN-C), an extracellular matrix protein, promotes GBM growth and invasion.
  • Current treatments for GBM yield disappointing outcomes, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To evaluate a novel RNA interference (RNAi) therapy targeting tenascin-C (TN-C) in patients with resected brain tumors.
  • To assess the efficacy of post-surgical intervention with RNAi (iRNAi) in inhibiting TN-C synthesis and its impact on patient outcomes.
  • To investigate the potential of RNAi as a therapeutic modality for human brain tumors.

Main Methods:

  • A clinical study involving 46 patients with resected brain tumors treated with double-stranded RNA (dsRNA) targeting TN-C mRNA (ATN-RNA).
  • In vitro validation using glioblastoma multiforme cultured cells to confirm TN-C downregulation by ATN-RNA.
  • Assessment of patient outcomes including overall survival (OS), quality of life (QOL), and tumor recurrence via MRI and CT scans.

Main Results:

  • ATN-RNA effectively downregulated TN-C expression in glioblastoma multiforme cells.
  • Patients treated with ATN-RNA showed a significant improvement in overall survival (OS).
  • No loss in quality of life (QOL) was observed, and imaging studies indicated delayed tumor growth or absence of recurrence.

Conclusions:

  • Post-surgical intervention with RNAi (iRNAi) targeting TN-C represents a novel and potentially effective therapeutic strategy for human brain tumors.
  • This RNAi-based therapy shows promising therapeutic potential for glioblastoma multiforme, improving survival and delaying recurrence.
  • The iRNAi method is the first reported protocol for RNAi application in human brain tumor treatment.

More Related Videos

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...